+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Lack of predictive value of reticulocalbin-1 and GST-Pai alterations for efficacy of postoperative adjuvant chemotherapy consisting of cisplatin plus vindesine in patients with p-stage IIIA-N2 non-small cell lung cancer (NSCLC) (JCOG9304A)



Lack of predictive value of reticulocalbin-1 and GST-Pai alterations for efficacy of postoperative adjuvant chemotherapy consisting of cisplatin plus vindesine in patients with p-stage IIIA-N2 non-small cell lung cancer (NSCLC) (JCOG9304A)



Journal of Clinical Oncology 23(16_Suppl): 7316-7316



NlmCategory="UNASSIGNED">7316 Background: We have been sought for molecular markers for prediction of prognosis or chemo-sensitiby to achieve "individualized therapy". We detected a polypeptide (molecular weight 44.0 kDa) which significantly decreased in expression level in CDDP-resistant cells by comparing the two-dimensional polyacrylamide gel electrophoresis (2-DE) patterns of the parent strain and CDDP-resistant cultured lung cancer cells (H69 and PC14). The amino acid sequence suggested that this polypeptide might be homologous with reticulocalbin-1 (RCN-1). In our in-house cases with adjuvant chemotherapy using platinum-based drugs with positive expression of RCN-1 was a better outcome obtained compared with cases without RCN-1 expression. To evaluate which molecular markers would be define subset of patients who would be benefited from postoperative adjuvant chemotherapy. Abnormal expression of RCN-1 and GST-Pai. was detected in 76% and 42%, respectively. There was no relationship between each molecular alteration and clinical-pathologic characteristics such as gender, age, or treatment arm. In addition, in none of patient subsets with or without above molecular markers, survival was significantly affected by postoperative adjuvant chemotherapy (RCN-1+P=0.2980, RCN-1-P=0.5873; GST-pai+P=0.7291, GST-pai-P=0.3398). Although the number of patients was small and our previous study suggested the reticulocalbin-1 molecule might have some kind of involvement in the chemical tolerance mechanism of platinum-based drugs, it is concluded that in this retrospective analysis these markers failed to predict survival or response to the adjuvant chemotherapy consisting of cisplatin and vindesine in NSCLC patients with N2 disease. No significant financial relationships to disclose.

(PDF emailed within 1 workday: $29.90)

Accession: 058194573

Download citation: RISBibTeXText

PMID: 27945068


Related references

A randomized phase III trial of adjuvant chemotherapy with cisplatin and vindesine followed by UFT for completely resected pathologic (p-) stage IIIA-N2 non-small cell lung cancer (NSCLC): West Japan Study Group for Lung Cancer Surgery (WJSG) - the 5 th Study. Journal of Clinical Oncology 23(16_Suppl): 7262-7262, 2016

Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). European Journal of Cardio-Thoracic Surgery 15(4): 438-443, 1999

Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer 49(1): 85-94, 2005

A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA non-small cell lung cancer. Journal of Medical Investigation 65(1.2): 90-95, 2018

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial. Lung Cancer 47(1): 103-109, 2004

Randomized phase ii evaluation of preoperative radiation therapy xrt and chemotherapy with mitomycin c vinblastine and cisplatin mvp for patients with pathologic stage iiia and iiib non small cell lung cancer nsclc. International Journal of Radiation Oncology, Biology, Physics 19(SUPPL 1): 144, 1990

Randomized phase II evaluation of preoperative radiation therapy (XRT) and chemotherapy with mitomycin-C, vinblastine, and cisplatin (MVP) for patients with pathologic stage IIIA and IIIB non-small cell lung cancer (NSCLC). International Journal of Radiation Oncology*biology*physics 19(Supp-S1): 144-0, 1990

Short-schedule cisplatin and vinorelbine as induction chemotherapy in stage IIIA(N2)-IIIB non small cell lung cancer (NSCLC). Journal of Clinical Oncology 23(16_Suppl): 7267-7267, 2016

Feasibility of adjuvant cisplatin and gemcitabine in patients who have undergone complete resection of stage IB-IIIA non-small cell lung cancer (NSCLC): Preliminary report of a feasibility trial in Japanese patients. Journal of Clinical Oncology 26(15_Suppl): 18503-18503, 2016

Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine. ChemoTherapy 59(4): 307-313, 2014

Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC). Lung Cancer 37(1): 65-71, 2002

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). Journal of Thoracic and Cardiovascular Surgery 129(5): 977-983, 2005

Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. International Journal of Radiation Oncology, Biology, Physics 72(3): 695-701, 2008

Toxicity and Efficacy of Sequential Chemotherapy in Patients with p-stage I Non-small Cell Lung Cancer that Recurring during Postoperative Tegafur-Uracil Adjuvant Chemotherapy. Cancer Investigation 36(8): 424-430, 2018

Combination chemotherapy of non small cell lung cancer nsclc with mitomycin mmc vindesine vds and cisplatin ddp. Cancer Immunology Immunotherapy 23(SUPPL): A39, 1986